BioWorld

May 13, 2002

ViroPharma Prepares To Receive Not Approvable' Picovir Letter

The FDA is not expected to grant ViroPharma Inc. regulatory clearance for its cold medicine that has been criticized for reducing the duration of illness by only one day. (BioWorld Today) Read More

Wyeth Stops Heart Attack Study; Neose Loses Manufacturing Deal

TIGR Deploys Sequence-Based Genomic Analyses To Compare Suspect Anthrax Strain Variants

Isotechnika, Roche To Focus On Transplantation; RA Trial Delayed

Other News To Note

Gliatech Files For Chapter 11 Following Product Setbacks

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for April 6, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis

BioWorld Science

Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...